CDDO-me protects normal lung and breast epithelial cells but not cancer cells from radiation

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  El Ashmawy, Mariam ^a   Delgado, Oliver ^b   Cardentey, Agnelio ^a   Wright, Woodring E ^a   Shay, Jerry W ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

BARDOXOLONE METHYL; TRANSCRIPTION FACTOR NRF2; ANTIOXIDANT; METHYL 2-CYANO-3,12-DIOXOOLEAN-1,9-DIEN-28-OATE; OLEANOLIC ACID; RADIOPROTECTIVE AGENT;

ANIMAL CELL; ARTICLE; BREAST CANCER CELL LINE; BREAST EPITHELIUM; BRONCHUS MUCOSA; CANCER CELL; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG EFFECT; DRUG EFFICACY; EMBRYO; GAMMA RADIATION; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM; LUNG CANCER CELL LINE; LYMPHOCYTE; MOUSE; NONHUMAN; PROTEIN FUNCTION; PROTEIN INDUCTION; RADIATION PROTECTION; ANALOGS AND DERIVATIVES; ANIMAL; BREAST; BREAST NEOPLASMS; CELL LINE; CYTOLOGY; DRUG EFFECTS; EPITHELIUM CELL; FEMALE; LUNG; LUNG NEOPLASMS; METABOLISM; RADIATION RESPONSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTIOXIDANTS; BREAST; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; DNA DAMAGE; EPITHELIAL CELLS; FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; MICE; NF-E2-RELATED FACTOR 2; OLEANOLIC ACID; RADIATION-PROTECTIVE AGENTS; SIGNAL TRANSDUCTION;

EID: 84919636116     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115600     Document Type: Article

References (39)

1. Ward JF (1988) DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of formation, and reparability. Prog Nucleic Acid Res Mol Biol 35: 95-125.
2. Bernier J, Hall EJ, Giaccia A (2004) Radiation oncology: a century of achievements. Nat Rev Cancer 4: 737-747.
3. Cucinotta FA, Chappell LJ, Kim MH, Wang M (2012) Radiation carcinogenesis risk assessments for never-smokers. Health Phys 103: 643-651.
4. Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, et al. (2012) Radiation exposure from CTscans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet 380: 499-505.
5. Newhauser WD, Durante M (2011) Assessing the risk of second malignancies after modern radiotherapy. Nat Rev Cancer 11: 438-448.
6. Ray PD, Huang BW, Tsuji Y (2012) Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal 24: 981-990.
7. Mitsuishi Y, Motohashi H, Yamamoto M (2012) The Keap1-Nrf2 system in cancers: stress response and anabolic metabolism. Front Oncol 2: 200.
8. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, et al. (2006) Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 3: e420.
9. Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, et al. (2010) Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 16: 3743-3753.
10. Honda T, Yoshizawa H, Sundararajan C, David E, Lajoie MJ, et al. (2011) Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents. J Med Chem 54: 1762-1778.
11. Liby K, Royce DB, Williams CR, Risingsong R, Yore MM, et al. (2007) The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res 67: 2414-2419.
12. Liby KT, Sporn MB (2012) Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev 64: 972-1003.
13. Hong DS, Kurzrock R, Supko JG, He X, Naing A, et al. (2012) A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res 18: 3396-3406.
14. Liby K, Risingsong R, Royce DB, Williams CR, Yore MM, et al. (2008) Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDOmethyl Ester and the rexinoid LG100268. Clin Cancer Res 14: 4556-4563.
15. Liby K, Risingsong R, Royce DB, Williams CR, Ma T, et al. (2009) Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice. Cancer Prev Res (Phila) 2: 1050-1058.
16. Wang YY, Zhe H, Zhao R (2014) Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment. Mol Cancer 13: 30.
17. Liby K, Hock T, Yore MM, Suh N, Place AE, et al. (2005) The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res 65: 4789-4798.
18. Liby KT, Royce DB, Risingsong R, Williams CR, Maitra A, et al. (2010) Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. Cancer Prev Res (Phila) 3: 1427-1434.
19. Daroczi B, Kari G, Ren Q, Dicker AP, Rodeck U (2009) Nuclear factor kappaB inhibitors alleviate and the proteasome inhibitor PS-341 exacerbates radiation toxicity in zebrafish embryos. Mol Cancer Ther 8: 2625-2634.
20. Kim SB, Pandita RK, Eskiocak U, Ly P, Kaisani A, et al. (2012) Targeting of Nrf2 induces DNA damage signaling and protects colonic epithelial cells from ionizing radiation. Proc Natl Acad Sci U S A 109: E2949-2955.
21. Eskiocak U, Kim SB, Roig AI, Kitten E, Batten K, et al. (2010) CDDO-Me protects against space radiation-induced transformation of human colon epithelial cells. Radiat Res 174: 27-36.
22. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, et al. (2004) Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 64: 9027-9034.
23. Sato M, Vaughan MB, Girard L, Peyton M, Lee W, et al. (2006) Multiple oncogenic changes (KRAS (V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res 66: 2116-2128.
24. Shay JW, Tomlinson G, Piatyszek MA, Gollahon LS (1995) Spontaneous in vitro immortalization of breast epithelial cells from a patient with Li-Fraumeni syndrome. Mol Cell Biol 15: 425-432.
25. Shay JW, Van Der Haegen BA, Ying Y, Wright WE (1993) The frequency of immortalization of human fibroblasts and mammary epithelial cells transfected with SV40 large T-antigen. Exp Cell Res 209: 45-52.
26. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, et al. (2001) Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci U S A 98: 3410-3415.
27. Pike MC, Alper T (1964) A Method for Determining Dose-Modification Factors. Br J Radiol 37: 458-462.
28. Gyori BM, Venkatachalam G, Thiagarajan PS, Hsu D, Clement MV (2014) OpenComet: An automated tool for comet assay image analysis. Redox Biol 2: 457-465.
29. Casas F, Vinolas N (2004) Toxicity of small cell lung cancer treatment. Hematol Oncol Clin North Am 18: 461-481.
30. Andreassen CN, Grau C, Lindegaard JC (2003) Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy. Semin Radiat Oncol 13: 62-72.
31. Wasserman TH, Brizel DM (2001) The role of amifostine as a radioprotector. Oncology (Williston Park) 15: 1349-1354; discussion 1357-1360.
32. Radford EP (1980) Human health effects of low doses of ionizing radiation: the BEIR III controversy. Radiat Res 84: 369-394.
33. Meadows AT, Gallagher JA, Bunin GR (1992) Late effects of early childhood cancer therapy. Br J Cancer Suppl 18: S92-95.
34. Kim YH, Yoo KC, Cui YH, Uddin N, Lim EJ, et al. (2014) Radiation promotes malignant progression of glioma cells through HIF-1alpha stabilization. Cancer Lett 354: 132-141.
35. Koukourakis MI, Giatromanolaki A, Chong W, Simopoulos C, Polychronidis A, et al. (2004) Amifostine induces anaerobic metabolism and hypoxia-inducible factor 1 alpha. Cancer Chemother Pharmacol 53: 8-14.
36. Levy S, Forman HJ (2010) C-Myc is a Nrf2-interacting protein that negatively regulates phase II genes through their electrophile responsive elements. IUBMB Life 62: 237-246.
37. Shanmugam MK, Dai X, Kumar AP, Tan BK, Sethi G, et al. (2014) Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: preclinical and clinical evidence. Cancer Lett 346: 206-216.
38. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, et al. (2011) Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365: 327-336.
39. Liby KT (2014) Synthetic triterpenoids can protect against toxicity without reducing the efficacy of treatment with Carboplatin and Paclitaxel in experimental lung cancer. Dose Response 12: 136-151.